FLGC · Flora Growth Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.27M | - | $9.75M | $14.80M | $11.79M | - | $12.46M | $15.68M | $18.03M | - |
| Cost of Revenue | $4.13M | - | $9.41M | $11.97M | $8.90M | - | $9.63M | $12.52M | $14.18M | - |
| Gross Profit | $3.15M | - | $335.0K | $2.83M | $2.89M | - | $2.84M | $3.17M | $3.85M | - |
| R&D | - | - | - | $73.0K | $113.0K | - | $118.0K | $62.0K | $47.0K | - |
| SG&A | - | - | $473.0K | $760.0K | $470.0K | - | $416.0K | $587.0K | $442.0K | - |
| Total Operating Expenses | $65.80M | - | $3.60M | $5.40M | $3.87M | - | $6.53M | $6.71M | $6.34M | - |
| D&A | $4.0K | - | $7.0K | $195.0K | $182.0K | - | $226.0K | $257.0K | $74.0K | - |
| Operating Income | ($62.65M) | - | ($3.27M) | ($2.57M) | ($977.0K) | - | ($3.69M) | ($3.54M) | ($2.48M) | - |
| Interest Expense | $66.0K | - | - | - | - | - | - | - | - | - |
| Income Tax | ($9.0K) | - | $18.0K | ($48.0K) | $38.0K | - | ($164.0K) | ($35.0K) | $128.0K | - |
| Net Income | ($36.66M) | - | ($6.66M) | ($2.41M) | ($758.0K) | - | ($3.77M) | ($2.63M) | ($3.37M) | - |
| EPS - Basic | ($3.68) | - | ($9.05) | ($0.11) | ($0.04) | - | ($0.28) | ($0.21) | ($0.38) | - |
| EPS - Diluted | ($3.68) | - | ($9.05) | ($0.11) | ($0.04) | - | ($0.28) | ($0.21) | ($0.38) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.98M | $5.60M | $13.10M | $1.47M | $3.68M | $6.02M | $4.21M | $6.13M | $4.16M | $4.35M |
| Accounts Receivable | $783.0K | $799.0K | $2.29M | $5.09M | $4.05M | $3.06M | $3.92M | $3.28M | $3.22M | $3.95M |
| Inventory | $1.61M | $1.90M | $2.48M | $4.80M | $4.79M | $5.77M | $7.86M | $6.75M | $9.25M | $8.51M |
| Accounts Payable | $2.48M | $2.33M | $2.96M | $3.81M | $3.87M | $5.46M | $6.65M | $4.62M | $5.00M | $5.11M |
| Current Assets | $11.25M | $8.72M | $18.09M | $13.20M | $13.22M | $19.76M | $21.29M | $21.36M | $21.77M | $21.36M |
| Total Assets | $45.19M | $130.24M | $74.02M | $22.67M | $22.39M | $26.23M | $29.28M | $30.08M | $24.27M | $23.63M |
| Current Liabilities | $8.10M | $8.63M | $8.70M | $13.81M | $12.59M | $18.83M | $20.89M | $18.38M | $19.32M | $16.28M |
| Long-term Debt | $38.0K | $50.77M | $64.0K | $326.0K | $275.0K | $2.08M | - | - | - | - |
| Total Liabilities | $8.39M | $59.68M | $9.10M | $18.64M | $17.64M | $21.72M | $24.10M | $21.81M | $21.14M | $17.22M |
| Stockholders' Equity | $36.80M | $70.55M | $64.92M | $4.02M | $4.76M | $4.51M | $4.25M | $7.31M | $3.14M | $6.40M |
| Retained Earnings | ($314.45M) | ($277.79M) | ($167.88M) | ($161.31M) | ($158.90M) | ($158.14M) | ($152.01M) | ($148.24M) | ($145.62M) | ($142.55M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.85M) | - | - | - | ($2.73M) | - | - | - | ($1.34M) | - |
| Investing Cash Flow | $0 | - | - | - | $437.0K | - | - | - | ($88.0K) | - |
| Financing Cash Flow | $571.0K | - | - | - | $0 | - | - | - | $1.19M | - |
| CapEx | $0 | - | - | - | $24.0K | - | - | - | $88.0K | - |
| Free Cash Flow | ($3.85M) | - | - | - | ($2.75M) | - | - | - | ($1.43M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 43.2% | - | 3.4% | 19.1% | 24.5% | - | 22.8% | 20.2% | 21.4% | - |
| Operating margin | -861.3% | - | -33.5% | -17.3% | -8.3% | - | -29.6% | -22.6% | -13.8% | - |
| EBITDA margin | -861.3% | - | -33.4% | -16.0% | -6.7% | - | -27.8% | -20.9% | -13.4% | - |
| Net margin | -504.0% | - | -68.3% | -16.3% | -6.4% | - | -30.3% | -16.8% | -18.7% | - |
| Free cash flow margin | -52.9% | - | - | - | -23.3% | - | - | - | -7.9% | - |
| FCF / Net income | 0.10 | - | - | - | 3.63 | - | - | - | 0.42 | - |
| R&D / Revenue | - | - | - | 0.5% | 1.0% | - | 0.9% | 0.4% | 0.3% | - |
| SG&A / Revenue | - | - | 4.9% | 5.1% | 4.0% | - | 3.3% | 3.7% | 2.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -81.1% | - | -9.0% | -10.6% | -3.4% | - | -12.9% | -8.7% | -13.9% | - |
| Return on equity | -99.6% | - | -10.3% | -60.0% | -15.9% | - | -88.8% | -36.0% | -107.5% | - |
| Return on invested capital | -134.4% | - | -4.0% | -46.6% | -15.3% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.39 | 1.01 | 2.08 | 0.96 | 1.05 | 1.05 | 1.02 | 1.16 | 1.13 | 1.31 |
| Quick ratio | 1.19 | 0.79 | 1.79 | 0.61 | 0.67 | 0.74 | 0.64 | 0.79 | 0.65 | 0.79 |
| Cash ratio | 0.24 | 0.65 | 1.51 | 0.11 | 0.29 | 0.32 | 0.20 | 0.33 | 0.22 | 0.27 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.72 | 0.00 | 0.08 | 0.06 | 0.46 | - | - | - | - |
| Debt / Assets | 0.00 | 0.39 | 0.00 | 0.01 | 0.01 | 0.08 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -949.3x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.23 | 1.85 | 1.14 | 5.63 | 4.71 | 5.82 | 6.89 | 4.12 | 7.74 | 3.69 |
| Liabilities / Assets | 0.19 | 0.46 | 0.12 | 0.82 | 0.79 | 0.83 | 0.82 | 0.72 | 0.87 | 0.73 |
| Efficiency | ||||||||||
| Asset turnover | 0.16 | - | 0.13 | 0.65 | 0.53 | - | 0.43 | 0.52 | 0.74 | - |
| Inventory turnover | 2.56 | - | 3.79 | 2.49 | 1.86 | - | 1.23 | 1.86 | 1.53 | - |
| Days sales outstanding | 39d | - | 86d | 126d | 125d | - | 115d | 76d | 65d | - |
| Days inventory outstanding | 143d | - | 96d | 146d | 197d | - | 298d | 197d | 238d | - |
| Days payable outstanding | 219d | - | 115d | 116d | 159d | - | 252d | 135d | 129d | - |
| Cash conversion cycle | -37d | - | 67d | 156d | 163d | - | 160d | 138d | 174d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -38.3% | - | -21.8% | -5.7% | -34.6% | - | 28.4% | -26.9% | -10.3% | - |
| Revenue CAGR (3y) | -28.7% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 8.9% | - | -88.2% | -10.6% | -25.1% | - | -39.4% | -20.0% | 44.3% | - |
| Operating income growth (YoY) | -6312.8% | - | 11.5% | 27.5% | 60.7% | - | -583.7% | 91.2% | 67.6% | - |
| Net income growth (YoY) | -4736.4% | - | -76.5% | 8.3% | 77.5% | - | - | 89.3% | 55.8% | - |
| EPS growth (YoY) | -9100.0% | - | -3132.1% | 47.6% | 89.5% | - | - | 96.8% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -39.8% | - | - | - | -92.7% | - | - | - | 78.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 673.4% | 1464.3% | 1427.5% | -45.0% | 51.6% | -29.6% | -70.3% | -33.2% | -94.2% | -88.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Geographic
$59.51M totalDE$35.87M · 60.3%
US$22.24M · 37.4%
GB$728.0K · 1.2%
AU$671.0K · 1.1%
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing Flora Growth Corp. against the 5 most active filers in the same SIC group.